Table of Content

1. Introduction to Dopamine Cell Therapy
1.1 Utilizing Dopamine To Treat Neurodegenerative Diseases
1.2 Evolution of Dopamine Into Cell Replacement Therapy


2. Dopamine Cell Therapy - Mechanism Of Action
2.1 Stem Cell Based Approaches
2.2 Fetal Cell Replacement


3. Global Dopamine Cell Replacements Therapy Clinical Trials Overview
3.1 By Company
3.2 By Country
3.3 By Indication
3.4 By Phase


4. Global Dopamine Cell Replacement Therapy Clinical Trials By Company, Indication & Phase
4.1 Research
4.2 Preclinical
4.3 Phase-I
4.4 Phase-I/II
4.5 Preregistration


5. Current Dopamine Cell Therapy Market Scenario
5.1 Regulatory Designations
5.2 Clinical Stance
5.3 Market Trends, Collaborations, Licensing & Financing


6. Dopamine Cell Replacement Therapeutic Approach By Company


7. Dopamine Cell Therapy Market Dynamics
7.1 Market Drivers
7.2 Market Challenges


8. Dopamine Cell Replacement Therapy Future Outlook


9. Competitive Landscape
9.1 Aspen Neuroscience
9.2 BlueRock Therapeutics
9.3 Sumitomo Pharma
9.4 Tel Aviv University
9.5 The Scripps Research Institute



List of Figures

Figure 3-1: Global - Dopamine Cell Replacement Therapy Clinical Trials By
Company, 2023
Figure 3-2: Global - Dopamine Cell Replacement Therapy Clinical Trials By Country 2023
Figure 3-3: Global - Dopamine Cell Replacement Therapy Clinical Trials By
Indication, 2023
Figure 3-4: Global - Dopamine Cell Replacement Therapy Clinical Trials By Phase 2023

Figure 5-1: FDA Drug Approval Pathways
Figure 5-2: Clinical Development Strategy & Drug Approval By FDA
Figure 5-3: Multidisciplinary Product Development Strategies

Figure 6-1: Differentiation of Neural Precursor Cells in TED
Figure 6-2: TED Technology Mechanism
Figure 6-3: Expandability of TED Technology Platform
Figure 6-4: TED Technology used to Develop TED-A9
Figure 6-5: Clinical Pipeline of Aspen Neuroscience
Figure 6-6: Aspen Neuroscience’s Autologous Cell Replacement Therapy
Figure 6-7: BlueRock Therapeutics – Authentic Cells
Figure 6-8: Production of MSC-NTF Cells
Figure 6-9: Multiple Applications of Innervace’s Technology Platform
Figure 6-10: Innervace - Bioengineered Live Active Neurons
Figure 6-11: Advantages & Opportunities Associated with Innervace’s Technology
Figure 6-12: FUJIFILM Cellular Dynamics – Making Induced Pluripotent Stem Cells
Figure 6-13: Sumitomo Pharma – iPS Drug Discovery Technology

Figure 7-1: Dopamine Cell Replacement Therapy Market Drivers
Figure 7-2: Dopamine Cell Replacement Therapy Market Challenges

Figure 8-1: Dopamine Cell Replacement Therapy Future Outlook